Skip to main content
. 2017 May 2;8(33):54604–54615. doi: 10.18632/oncotarget.17554

Figure 4. Kaplan Meier survival analysis for combined LC3B dot like/p62 dot like-cytoplasmic staining for subgroups.

Figure 4

(A) Tumors with adjuvant treatment (B) non-metastasized tumors (i.e. UICC/AJCC stages I-II) (C) left sided carcinomas (D) MMR proficient carcinomas